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Cognitively normalThe objective of our study was to evaluate whether cognitively normal (CN) elderly participants showing
elevated cortical beta-amyloid (Aβ) deposition have a consistent neuroanatomical signature of brain atrophy that
may characterize preclinical Alzheimer's disease (AD). 115 CN participants who were Aβ-positive (CN+) by amy-
loid PET imaging; 115 CN participants who were Aβ-negative (CN−); and 88 Aβ-positive mild cognitive impair-
ment or AD participants (MCI/AD+) were identiﬁed. Cortical thickness (FreeSurfer) and gray matter volume
(SPM5) were measured for 28 regions-of-interest (ROIs) across the brain and compared across groups. ROIs that
best discriminated CN− from CN+ differed for FreeSurfer cortical thickness and SPM5 gray matter volume.
Group-wise discriminationwas poorwith a high degree of uncertainty in terms of the rank ordering of ROIs. In con-
trast, both techniques showed strong and consistent ﬁndings comparing MCI/AD+ to both CN− and CN+ groups,
with entorhinal cortex, middle and inferior temporal lobe, inferior parietal lobe, and hippocampus providing the
best discrimination for both techniques. Concordance across techniques was higher for the CN− and CN+ versus
MCI/AD+ comparisons, compared to the CN− versus CN+ comparison. The weak and inconsistent nature of the
ﬁndings across technique in this study cast doubt on the existence of a reliable neuroanatomical signature of preclin-
ical AD in elderly PiB-positive CN participants.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction
Alzheimer's disease (AD) is characterized by the deposition of
beta-amyloid (Aβ) senile plaques and tau-positive neuroﬁbrillary
tangles (NFTs) in the brain (Braak and Braak, 1991). It is associated
with characteristic patterns of atrophy preferentially involving me-
dial and lateral temporal lobes, and parietal and frontal association cor-
tices. In concordance with the topographic progression of NFTs (Braak
and Braak, 1991) at autopsy, early atrophic changes have been observed
in entorhinal cortex and hippocampus, before spreading through-
out temporal and parietal lobes, and then later affecting frontal lobes
(Whitwell et al., 2007). Several studies assessing cognitively normal, Rochester, MN 55905, USA.
hitwell).
nc. Open access under CC BY license.(CN) subjects who show positive Aβ PET scanning, and hence presumed
preclinical AD (Sperling et al., 2011), have observed atrophy in these
subjects (Dickerson et al., 2009a, 2011; Mormino et al., 2009; Storandt
et al., 2009; Becker et al., 2011; Bourgeat et al., 2010; Chetelat et al.,
2010; Oh et al., 2010), with some reporting a direct link between the
presence of Aβ and atrophy in the frontal and parietal cortices (Becker
et al., 2011; Chetelat et al., 2010; Oh et al., 2010). One of these studies
even suggested that these Aβ-related neocortical neurodegenerative
changes may occur prior to neurodegeneration in the medial temporal
lobe (Becker et al., 2011). This challenges the topographic pattern
of progression in AD, and has important consequences for the cur-
rent model of pathological sequences in AD which proposes that
Aβ deposition precedes tau deposition and that tau deposition
leads to neurodegeneration (Jack et al., 2010).
The aim of this study was therefore to evaluate evidence for a neuro-
anatomical signature of Aβ deposition in a cohort of CN elderly who had
undergone Aβ PET scanning with Pittsburgh Compound B (PiB). Since
the majority of studies that associated atrophy with Aβ deposition
utilized FreeSurfer software and those that associated atrophy with tau
250 J.L. Whitwell et al. / NeuroImage: Clinical 2 (2013) 249–257deposition utilized Statistical Parametric Mapping (SPM) software, we
utilized both techniques in the current study to determine whether
differences in the literature could be driven in part by variability due to
technique and whether a consistent neuroanatomic signature of Aβ
deposition could be identiﬁed across technique.2. Design and methods
2.1. Participant selection
We identiﬁed all CN participants from the Mayo Clinic Alzheimer's
Disease Research Center (ADRC) or the Mayo Clinic Study of Aging
(MCSA) with PiB-PET andMRI (n=330). These participants were divid-
ed into PiB-negative (CN−) (n=215) or PiB-positive (CN+) (n=115)
based on methods described below. In order to control for possible
confounding due to age, sex, and education, we compared all 115 CN+
participants to a matched set of 115 CN− participants (matching using
propensity scores; D'Agostino, 1998). In addition to assessing differences
between CN− and CN+ participants, we wanted to assess atrophy in a
group with a known and homogeneous neuroanatomical signature.
Therefore, we identiﬁed a group of ADRC or MCSA patients with clinical
diagnoses of amnestic MCI or AD who were PiB-positive (MCI/AD+)
(n=88). Demographics of the groups are shown in Table 1).
The ADRC recruits individuals seekingmedical care at theMayo Clinic
and the MCSA is an epidemiologic study of normal aging and MCI in
70–90 year olds in Olmsted County, Minnesota (Roberts et al., 2008);
both are prospective longitudinal studies that perform similar clinical
and cognitive assessments and identical imaging protocols. In all cases
the most recent MRI was used for analysis and the PiB scan was
performed within 5 months of the MRI (median interval=20 days).
Diagnoses weremade on a clinical basis at consensus conferences in-
cluding neurologists, neuropsychologists, a neuropsychiatrist and study
coordinators (Roberts et al., 2008; Petersen et al., 2010). Participants
were characterized as CN if they were judged to be cognitively normal
and their age-adjusted neuropsychological test scores were consistent
with normative data developed independently in this community
(Ivnik et al., 1992). The presence/absence of subjective memory
complaints in the CN subjects was measured based on the ﬁrst 5
questions from the Blessed Memory Test, as previously detailed
(Mielke et al., 2012). The diagnosis of amnestic MCI was made on
clinical grounds, based on the presence of memory complaints and
impairment on psychometric testing, without the use of rigid cutoffs
on psychometric scores (Petersen, 2004). Alzheimer's diseasewas diag-
nosed using established criteria (McKhann et al., 1984). Informed con-
sent was obtained from all participants or proxies for participation in
the studies, which were approved by the Mayo Institutional Review
Board.Table 1
Participant demographics.
CN−
(n=115)
CN+
(n=115)
No. of females (%) 52 (45) 49 (43)
Age, years 80 (71, 92) 80 (60, 93)
Education, years 14 (11, 20) 15 (8, 20)
Short Test of Mental Status score 35 (27, 38) 35 (29, 38)
CDR Sum of Boxes 0.0 (0, 1.5) 0.0 (0, 1.5)
No. APOE ε4 positive (%)b 19 (17) 41 (38)
Subjective memory complaints (%)c 83 (73%) 97 (86%)
Note: Unless otherwise indicated, values shown are median (range).
Abbreviations: CN−, cognitively normal and negative for PiB (deﬁned as b1.5); CN+, c
impairment or Alzheimer's disease and positive for PiB (deﬁned as >1.5); CDR, Clinical De
a Converted from the Mini Mental State Exam for some participants.
b Twenty-one patients had unknown APOE status (3 in CN−, 8 in CN+, and 10 in MCI/A
c Data available in 113 CN− and 113 CN+ subjects.2.2. PiB PET processing and classiﬁcation
PET images were acquired using a PET/CT scanner (DRX; GE
Healthcare) operating in 3-dimensional mode. Participants were
injected with PiB (average, 596 MBq; range, 292–729 MBq) and after a
40 min uptake period a 20 min PiB scan was obtained consisting of
four 5-minute dynamic frames (256 m FOV; pixel size=1.0 mm; slice
thickness=3.3 mm).
PiB processingwas performed using an automated image processing
pipeline previously described in detail (Jack et al., 2008a). A global
cortical PiB retention summary was formed by calculating the median
uptake value among all voxels in prefrontal, orbitofrontal, parietal,
temporal, anterior cingulate, and posterior cingulate/precuneus regions
and dividing this by the median uptake in the cerebellar gray matter.
Participants were classiﬁed as PiB-positive or negative using a global
cortical-to-cerebellar ratio cut-point of 1.5 (Jack et al., 2008a).
2.3. MRI processing
All participants were imaged on a 3.0 T GE scanner with a 3Dmag-
netization prepared rapid acquisition gradient echo (MPRAGE) se-
quence (Jack et al., 2008b). Parameters were: sagittal plane, TR/TE/
TI, 2300/3/900 ms; ﬂip angle 8°, 26 cm ﬁeld of view (FOV);
256×256 in-plane matrix with a phase FOV of 0.94 and slice thick-
ness of 1.2 mm. All images were corrected for gradient non-linearity
and intensity inhomogeneity.
We used two common but substantively different techniques in our
analysis: cortical thickness estimates from FreeSurfer and volume esti-
mates from SPM5. FreeSurfer calculates cortical thickness using an esti-
mate of the width of the cortical gray matter (Fischl and Dale, 2000),
while SPM5 calculates volume based on segmenting tissue into gray
and white matter using prior probability maps (Ashburner and Friston,
2000). While these techniques assess two different metrics, both are
markers of cortical neurodegenerative atrophy. Assessing both tech-
niques allows us to ﬁrst determine whether we can replicate previ-
ous studies that have used these techniques, and secondly to assess
whether the two techniques provide consistent results which
would add strength to the proposition that Aβ is associatedwith a speciﬁc
pattern of neurodegeneration in preclinical AD. FreeSurfer cortical thick-
ness and SPM5 gray matter volume were used to assess ROI-derived
and whole-cortex/whole-brain patterns of atrophy in CN+ compared to
CN−, MCI/AD+ compared to CN− and MCI/AD+ compared to CN+.
2.3.1. FreeSurfer
FreeSurfer software version 4.5.0 (Dale et al., 1999; Fischl et al.,
1999) (http://surfer.nmr.mgh.harvard.edu/) was utilized. Brieﬂy, all
images underwent skull-stripping and transformations into TalaraichCN− versus CN+
P-value
MCI/AD+
(n=88)
CN− versus MCI/AD+
P-value
0.69 41 (47) 0.85
0.87 79 (51, 94) 0.34
0.46 14 (7, 20) 0.85
0.20 30 (4, 36)a b0.001
0.19 1.5 (0, 13.0) b0.001
b0.001 51 (65) b0.001
0.03 – –
ognitively normal and positive for PiB (deﬁned as >1.5); MCI/AD+, mild cognitive
mentia Rating scale; APOE, Apolipoprotein E.
D+).
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white boundary, automated topology correction, and surface deforma-
tion (Dale et al., 1999; Fischl and Dale, 2000). The resulting cortical
models were registered to a spherical atlas (Fischl et al., 1999). The
cerebral cortex was parcellated into regions based on gyral and sulcal
structure. The atlas used for parcellation was created using 40 normal
and AD participants. FreeSurfer outputted volume of hippocampus and
amygdala, and cortical thickness for all other ROIs. Vertex-level compar-
isons of cortical thickness were also performed across groups using
two sample t-tests after the spherical data was smoothed at 10 mm
full-width at half-maximum (FWHM). A very lenient Statistical thresh-
old of pb0.005 uncorrected for multiple comparisons was applied.
2.3.2. SPM5
Using SPM5 (http://ﬁl.ion.ucl.ac.uk), a customized template was
created using 200 CN and 200 AD participants (Vemuri et al., 2008). All
400 scans were normalized to the MNI template and segmented using
uniﬁed segmentation into gray matter (GM), white matter (WM) and
CSF. Average probability maps of GM, WM, and CSF were created
and smoothed using 8 mm FWHM smoothing kernel to create cus-
tomized tissue probability maps. Images from all subjects in the
study were then normalized and segmented using uniﬁed segmen-
tation and the customized tissue probability maps. Atlas-based
parcellation was performed using the automated anatomic labeling
(AAL) atlas (Tzourio-Mazoyer et al., 2002). The AAL atlas was nor-
malized to the customized template, and each ROI was edited on the
template in order to improve the accuracy of the atlas. In addition, the
AAL parahippocampal gyrus ROI was split into parahippocampal gyrus
and entorhinal cortex in order to better match the FreeSurfer atlas re-
gions. The atlas was then warped into participant native space using
the inverse transformations from above. Gray matter segmentations for
each participant were parcellated into ROIs using the native-space atlas
and graymatter volume estimated for each ROI. Voxel-level comparisons
were performed using voxel-based morphometry (VBM) (Ashburner
and Friston, 2000). The template-space segmented gray matter im-
ages were modulated for both the linear and non-linear components
and smoothed at 8 mm FWHM, and comparisons were performed
across groups using two sample t-tests, including TIV as a covariate.
A very lenient statistical threshold of pb0.005 uncorrected for multi-
ple comparisons was applied.
The atlases utilized in FreeSurfer and SPM5 differ, with FreeSurfer
parcellating the cortex into 80 ROIs (Desikan et al., 2006), and the AAL
atlas parcellating the cortex into 120 ROIs (Tzourio-Mazoyer et al.,
2002). Therefore, we created a common set of 28 new ROIs that covered
frontal, temporal, parietal, occipital lobes and insula. Supplemental Table
1 details how the individual ROIs from both techniques were utilized to
create the 28 new ROIs. Volumes were summed and cortical thickness
measures averaged to create the new ROIs. Supplemental Fig. 1 com-
pares the segmentations from both techniques for some examplemedial
regions. Left and right hemisphere volumeswere summed andwe calcu-
lated an average of left and right cortical thickness values weighted
according to the surface area of the ROIs using the following formula:
((left surface area∗ left thickness+right surface area∗right thickness)/
left+right surface area). All ROI volumes from FreeSurfer were divided
by the FreeSurfer total intracranial volume (TIV). Volumes from SPM5
were divided by a TIV calculated in SPM5 by propagating a template-
drawn TIV mask to the subject space, and then performing an erosion
step to remove border voxels. The FreeSurfer and SPM5 TIV measure-
ments were highly correlated (R=0.9). Since the thickness of most cor-
tical regions does not relate to head size, thickness measures were not
adjusted for TIV.
2.4. Statistical analysis
ROI-level analyses were based on two-sampleWilcoxon/Mann–
Whitney tests and summarized by the area under the receiver operatingcharacteristic curve (AUROC) which can be calculated directly from this
test and interpreted as ameasure of effect size independent of theunder-
lying scales ofmeasurement (Newcombe, 2006). For CN participants, the
AUROC can be interpreted as the proportion of times that an arbitrary
CN− participant would have greater cortical thickness (or volume) in
an ROI compared to an arbitrary CN+ participant. Values near 0.50 indi-
cate poor discrimination, while a value near, for example, 0.75 would in-
dicate that three-quarters of the time a CN+ participant would have
reduced gray matter compared to a CN− participant.
We present ROI-level AUROCs ranked from the highest/best
(rank=1) to the lowest/worst (rank=28). Because of the underlying
uncertainty in the rank of a given ROI due to sampling variability, we
include 95% bootstrap conﬁdence intervals for the rank of an ROI
based on B=1000 replicates. In addition, we calculated concordance
correlation coefﬁcients (CCC) to measure the agreement in terms of
ROI rank across the techniques.
In order to assess the inﬂuence of PiB cut-point the analyses were re-
peated utilizing a PiB cut-point of 1.4 and removing patients with inter-
mediate PiB values between 1.3 and 1.5. The analysis was also repeated
using FreeSurfer volume measurements rather than thickness in order
to account for any confounds related to these different measurements.
We used Spearman nonparametric correlations to examine the rela-
tionship between volume or thickness obtained from FreeSurfer and
volume obtained from SPM5.
3. Results
3.1. ROI-level analysis
Both FreeSurfer and SPM5 identiﬁed ROIs that were signiﬁcantly
different between CN− and CN+, with discrimination for the top ROIs
showing AUROCs in the 0.60 range (Fig. 1). For FreeSurfer cortical thick-
ness, the ﬁve ROIs that showed best discrimination were supramarginal
gyrus, fusiform gyrus, pars opercularis, posterior cingulate, and middle
frontal gyrus. For SPM5 gray matter volume, the ﬁve best ROIs were
medial orbitofrontal cortex, lateral orbitofrontal cortex, precuneus,
hippocampus, and pars triangularis. In addition to the disagreement in
terms of which ROIs provided the best discrimination, wide conﬁdence
intervals of equivalent magnitudes were observed for both techniques
indicating there is little certainty within a technique as to the top ROIs.
In contrast, results from FreeSurfer and SPM5 were more consistent
when comparing MCI/AD+ to both CN− and CN+ participants (Figs. 2
and 3). The entorhinal cortex,middle and inferior temporal gyrus, inferior
parietal lobe, andhippocampusprovided thebest discriminationbetween
CN− andMCI/AD+, with very similar regions identiﬁed in the compari-
sons of CN+ andMCI/AD+. Conﬁdence intervals for the rank of the ROIs
were relatively narrow allowing meaningful inferences about where the
greatest differences are to be found for both comparisons.
Overall, there was marginal discrimination ability and very poor
agreement across FreeSurfer and SPM5between ranks for discriminating
CN− versus CN+ (CCC=0.24) but much better discrimination ability
and agreement between the ranking for CN− versus MCI/AD+
(CCC=0.72) and CN+ versus MCI/AD+ (CCC=0.70) (Fig. 4).
Poor agreement across technique for discriminating CN− versus
CN+ was also observed when utilizing a PiB cut-point of 1.4 (CCC=
0.25), removing patients with PiB values between 1.3 and 1.5 (CCC=
0.09), and when utilizing FreeSurfer volume measurements rather than
thickness (CCC=0.39). Excellent agreement was observed across tech-
nique in all the CN− versus MCI/AD+ comparisons (CCC=0.75, 0.75
and 0.80 respectively).
Correlations between the techniques varied considerably across ROIs.
For all subjects, the median correlation across 28 ROIs was r=0.31
(range 0.02–0.72). Correlations between FreeSurfer volume and SPM5
volume were similarly variable (median r=0.45, range 0.20–0.72).
Correlations between FreeSurfer thickness and FreeSurfer volume were
somewhat higher on average (median r=0.58, 0.40–0.78).
Fig. 1. Forest plots illustrating ROI discrimination of CN− and CN+ participants for FreeSurfer and SPM5. Regions-of-interest are ranked from best (rank of 1) to worst (rank of 28)
according to AUROC and 95% bootstrap conﬁdence intervals are shown. The second y axis shows the AUROC values and p values.
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Small scattered regions of signiﬁcant differences were identiﬁed
between CN− and CN+ using both FreeSurfer and SPM5 at a very le-
nient statistical threshold of pb0.005 (Fig. 5). The most signiﬁcant
peaks were identiﬁed in inferior and orbital frontal lobe in SPM5, and
the entorhinal cortex, fusiform gyrus and lateral temporal, parietal
and frontal lobes in FreeSurfer. The reverse comparison showed re-
duced thickness in pericalcarine cortex in FreeSurfer in CN− compared
to CN+, but no regions that showed reduced volume in CN− compared
to CN+ in SPM5. Both techniques showed abnormalities predominantly
inmedial temporal, lateral temporoparietal, and posteromedial cortices
in MCI/AD+ compared to CN− , with similar, although less signiﬁcant,
ﬁndings observed in the comparison to CN+ (Fig. 5).4. Discussion
The question of whether AD-related neurodegeneration can be
detected in preclinical participants is critically important for the develop-
ment of early imaging biomarkers. Two commonly used imaging tech-
niques, FreeSurfer and SPM5, were utilized in this study to determine
whether a consistent neuroanatomic signature could be identiﬁed in
CN+ participants.
Each technique identiﬁed signiﬁcant regions of atrophy in CN+
participants compared to CN− participants, explaining the higher pro-
portion of subjectivememory complaints in the CN+ subjects. The pat-
terns of cortical thinning in the CN+ participants largely concurred
with previous FreeSurfer studies of this population (Dickerson et al.,
2009a, 2009b; Becker et al., 2011), and the patterns of gray matter
Fig. 2. Forest plots illustrating ROI discrimination of CN− and MCI/AD+ participants for FreeSurfer and SPM5. Regions-of-interest are ranked from best (rank of 1) to worst (rank of
28) according to AUROC and 95% conﬁdence intervals are shown. The second y axis shows the AUROC values and p values.
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utilized SPM5, with both identifying relationships between PiB deposi-
tion and hippocampal atrophy (Chetelat et al., 2010); suggesting rela-
tively consistent neuroanatomical signatures within technique. Despite
these consistencies, however, we did not ﬁnd consistent results across
the two measurement techniques, both in the identiﬁcation of most
discriminatory ROIs and in the overall patterns of atrophy. One striking
difference was that hippocampal volume was reduced in CN+ partici-
pants using SPM5, but not FreeSurfer. The hippocampus is of particular
interest because it is affected early in the disease in AD (Whitwell et al.,
2007). It is one of the ﬁrst structures to show tau deposition but is not
heavily affected by Aβ deposition (Braak and Braak, 1991). The SPM5
results would suggest that hippocampal atrophy could potentially be a
useful biomarker of preclinical AD in CN participants; likely reﬂecting
the concurrent presence of hippocampal tau and neocortical Aβ deposi-
tion (Chetelat et al., 2010) in these participants. However, the FreeSurfer
results suggest that hippocampal volume loss is not an early biomarkerof AD, but that thinning of heteromodal association cortices are the ear-
liest neuroanatomical changes, results that also replicate other prior
ﬁndings (Sabuncu et al., 2011).
There are a couple of possible ways to interpret our ﬁndings. First,
since the patterns of atrophy in CN+ participants appear somewhat
consistent within measurement technique across independent sam-
ples of participants, we could conclude that these are likely true bio-
logical effects. Differences observed across technique would then
suggest that patterns of cortical thickness reduction and volume
loss differ in these earliest stages of the disease, and that these two
techniques are providing fundamentally different types of measure-
ment of brain structure, as others have concluded (McKhann et al.,
1984; Newcombe, 2006). However, concordance across FreeSurfer
and SPM for the CN− versus CN+ comparison was still poor when
we assessed FreeSurfer volume rather than thickness, suggesting
that our ﬁndings do not reﬂect fundamental differences between
thickness and volume measures.
Fig. 3. Forest plots illustrating ROI discrimination of CN+ and MCI/AD+ participants for FreeSurfer and SPM5. Regions-of-interest are ranked from best (rank of 1) to worst (rank of 28)
according to AUROC and 95% conﬁdence intervals are shown. The second y axis shows the AUROC values and p values.
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ness and cortical volume are not intimately related, measurement difﬁ-
culties aside. Second, we could hypothesize that if any signature pattern
of graymatter loss in CN+ participants exists, the effects are subtle and
easily overshadowed by measurement error. Differences across tech-
niques could be driven by technical biases (Klauschen et al., 2009)
and neither pattern may completely reﬂect a true biological effect. The
high degree of variability between techniques and moderate correla-
tions in hippocampal volume across techniques (r=0.68 in CN− and
r=0.56 in CN+), despite being signiﬁcant (pb0.001), argues for this
explanation. More generally, correlations between FreeSurfer thickness
and SPM5 volume, FreeSurfer volume and SPM5 volume, or FreeSurfer
thickness and FreeSurfer volume were moderate at best. Also arguing
in favor of this latter explanation is the consistently weak discrimina-
tion ability of the “best”measures within each technique. The implica-
tions of this explanation would be that the presence of Aβ itself maynot directly cause atrophy, as others have suggested (Josephs et al.,
2008a; Dickerson et al., 2009b; Jack et al., 2010). It is also possible that
one of the techniques is “correct” in the sense of being able to detect
and localize differences in atrophy between CN+ and CN−, and the
other is incorrect. The accuracy of each techniquemay also vary region-
ally. There has been some suggestion that FreeSurfer is superior to SPM
in detecting subtle cortical pathology (McKhann et al., 1984; Klauschen
et al., 2009) and age-related gray matter loss (Hutton et al., 2009). The
degree of variability and discriminatory ability between CN− and CN+
was similar across techniques in this study however suggesting that this
explanation is unlikely. However, there has been little direct compari-
son of the two techniques to assess strengths and weaknesses, particu-
larly in the setting of subtle biological effects. The question of whether
differences observed between FreeSurfer and SPM are biological or
technical is still open, although this study demonstrates that evidence
for a neuroanatomical signature of Aβ in CN participants is weak and
Fig. 4. Plots illustrating concordance between the ranks of the 28 ROIs for FreeSurfer
and SPM5. The degree of agreement is shown as a concordance correlation coefﬁcient
(CCC). Concordance across techniques was good for the CN− and CN+ versus MCI/
AD+ comparisons, but poor for the CN− versus CN+ comparison.
255J.L. Whitwell et al. / NeuroImage: Clinical 2 (2013) 249–257hence that neuroanatomical patterns are unlikely to be useful bio-
markers of preclinical AD at the individual participant level.
In contrast to the ﬁndings in CN+ participants, the two techniques
showed very consistent results in MCI/AD+. The severity of atrophy in
MCI/AD+ was greater when compared to CN− subjects, rather than
CN+ subjects, reﬂecting the greater regional variability observed in the
CN+ group; although in both comparisons the results were consistent
across technique. Both techniques identiﬁed highly signiﬁcant and simi-
lar patterns of loss involving regions that are typical for AD and are very
similar to those identiﬁed in many previous studies using either image
analysis technique (Du et al., 2007; Whitwell et al., 2007). Therefore,
when the atrophic effects are larger there is considerable consistency
across techniques in their detection. Not surprisingly given the larger
effect sizes, conﬁdence in the results was high for this comparison,
with good agreement among ranks from the two techniques, less vari-
ability and excellent discrimination. This data supports the conclusion
in the paragraph above that cortical thickness and volume are intimately
related parameters. The distribution of atrophy identiﬁed in MCI/AD+,
along with ﬁndings from previous imaging-pathology studies (Gosche
et al., 2002; Jack et al., 2002; Josephs et al., 2008a; Whitwell et al.,
2008), point towards an association between atrophy and the topograph-
ically concurrent deposition of tau.
The strengths of our study include the fact thatwe had a large cohort
of well-matched CN participants, and that we utilized two different but
widely used and thoroughly validated image analysis techniques which
allowed us to assess consistency in the ﬁndings. Importantly, we also
demonstrate that our results were robust to varying the PiB cut-point.
The two techniques use different approaches to assess cortical gray
matter. Further, the atlases used to parcellate the brain differed across
techniques which meant that while we created a common set of 28
ROIs for each method, the boundaries of each ROI may not have been
identical. The templates used for normalization also differed across
technique although not dramatically. These technical differences may
contribute to the relatively poor cross-technique correspondence. In
addition, the averaging of left and right hemisphere volumes and thick-
nesses may have reduced sensitivity. Nevertheless, the consistent ﬁnd-
ings across technique in MCI/AD+ suggest that the two methods are
comparable when a larger disease effect is present. It will be crucial
for future studies to focus on technical comparisons, particularly to
identify the optimal technique for detecting the earliest signs of atrophy
in particular brain regions. The presence of subjective memory com-
plaints has also been suggested to inﬂuence the relationship between
amyloid deposition and atrophy (Chetelat et al., 2010), and will require
further investigation. Another important limitation of the study was
that while we had a measure of Aβ, we did not have a measure of tau
in these CN participants, so it is impossible to determine whether par-
ticipants with evidence of ﬁbrillar brain amyloid also have evidence of
substantial tau pathology. Other proteins are also often present in the
brains of AD participants that could inﬂuence the patterns of atrophy,
such as TDP-43 (Josephs et al., 2008b).
The weak and inconsistent nature of the ﬁndings across tech-
nique in this study cast doubt on the existence of a neuroanatomical
signature of preclinical AD in PiB-positive CN participants, and do not
support the suggestion that Aβ deposition is related to spatially coinci-
dent neurodegeneration. The topography of the SPM5 results suggests
a closer relationship between atrophy and tau pathology. However, de-
ﬁnitive resolution will need to await the availability of a fully validated
tau PET ligand (Fodero-Tavoletti et al., 2011).
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.nicl.2013.01.006.Role of the funding source
This studywas supported byNIHgrants P50-AG16574, U01-AG06786,
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